CClinicalTrials.gg
Sign In
CompletedNCT03747679Updated Jul 10, 2020

Palatability (Taste) of Oral Formulations of Bosutinib

A Phase 1 interventional study of 200 Mg capsules of bosutinib in Water solution and bosunitib sorbitol in CML, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-10.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Healthy Adult Volunteer Taste Study of Oral Formulations of Bosutinib for Pediatric Use. This will be a single-blind, randomized, multiple-period (dosing over 4 days) study in healthy male and/or female participants. Approximately 8 participants will assess the sensory attributes of different powder for oral suspension (POS) formulations.

Read the detailed description

Taste evaluations for the formulations (Formulations A to N) in Sessions 1 to 4 each contains 4 periods. All the planned formulations in this study will have a bosutinib amount equal to 200 mg in each taste assessment. Session 1 consists of bosutinib POS, sorbitol base in water (A); bosutinib POS, mannitol base in water (B); and bosutinib capsules to be opened into water (C). Session 2 consists of bosutinib POS, mannitol base in low % (D) and in high % (E) sodium saccharine sweetener vehicles, respectively; bosutinib POS, mannitol base in low % (F) and high % (G) strawberry flavour vehicles, respectively. Session 3 consists of bosutinib capsules to be opened into low % (H) and high % (I) sodium saccharine sweetener vehicles, respectively; bosutinib capsules to be opened into low % (J) and high % (K) strawberry flavour vehicles, respectively. Session 4 consists of bosutinib capsules opened onto apple sauce (L); bosutinib capsules opened onto full fat natural yoghurt (M); and bosutinib capsules to be opened into water (N). Participants will be assigned to one of the treatment sequences available for each session. Except at session 4 for treatments L and M, each formulation will be presented to the participants in a blinded fashion.

Participants will be required to not swallow, rather to only swish the bosutinib containing liquid in their mouths for approximately 10 seconds, after which the liquid will be spat out. Each participant will record the sensory attributes at timed intervals of 0 (immediately after dosing), 5, 10 and 20 minutes after spitting using a Bosutinib Taste Assessment Questionnaire.

02

Conditions studied

  • CML

Keywords

  • CML; palatability; taste; pediatric formulation
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.

Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Age and Sex:

  1. Female participants of non-childbearing potential and/or male participants able to father children must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD).

    -Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

    Type of Participant and Disease Characteristics:

  2. Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, limited physical examination, including blood pressure (BP) and pulse rate measurement, or clinical laboratory tests.

  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

    Weight:

  4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).

    Informed Consent:

  5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Exclusion criteria

Exclusion Criteria:

Medical Conditions:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. A history of hypersensitivity to the active compounds or to any inactive ingredients (excipients) contained in the formulations.
  3. Participants with conditions that affect their ability to taste - ie, dysgeusia, respiratory infection, cold, etc.
  4. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody (HCVAb). As an exception, a positive hepatitis B surface antibody (HBsAb) as a result of participant vaccination is permissible.

  5. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

    Prior/Concomitant Therapy:

  6. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. (Refer to Section 6.5 for additional details).

    Prior/Concurrent Clinical Study Experience:

  7. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product used in this study (whichever is longer).

    Diagnostic Assessments:

  8. A positive urine drug test.
  9. Use of tobacco-containing products.
  10. Screening supine blood pressure (BP) 140 mm Hg (systolic) or 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is 140 mm Hg (systolic) or 90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  11. Baseline 12 lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.

  12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 1.5 × upper limit of normal (ULN);
    • Total bilirubin level 1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ULN.

    Other Exclusions:

  13. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of consuming 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
  14. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  15. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  16. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
  17. Male participants with partners currently pregnant; male participants able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product or longer based upon the compound's half-life characteristics.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    A- Bosutinib in water

    200 Mg of bosutinib (50 mg capsule x4) in Water solution

    Drug: 200 Mg capsules of bosutinib in Water solution

  • Experimental
    B- bosutinib in sorbitol

    200 Mg of bosutinib sorbitol base in water solution

    Drug: bosunitib sorbitol

  • Experimental
    C- - bosutinib mannitol

    200 Mg of bosutinib powder mannitol base in water solution

    Drug: Bosutinib Mannitol

  • Experimental
    D - bosutinib in mannitol low sweet

    200 Mg of bosutinib mannitol low sweet solution

    Drug: bosutinib in mannitol low sweet

  • Experimental
    E- - bosutinib in mannitol high sweet

    200 Mg of bosutinib High % sweet mannitol solution

    Drug: bosutinib in mannitol high sweet

  • Experimental
    F- - bosutinib low flavour

    Taste assessment of 200 Mg of bosutinib low % Flavour

    Drug: bosutinib taste low flavour

  • Experimental
    G- bosutinib high flavour

    Taste assessment of 200 Mg of bosutinib high percentage of flavor in water

    Drug: bosutinib high flavour

  • Experimental
    H- - bosutinib capsules in low sweet

    Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet

    Drug: Bosutinib capsules in low sweet

  • Experimental
    I - bosutinib capsules high sweet

    200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener

    Drug: bosutinib capsules high sweet

  • Experimental
    J- - bosutinib capsules low flavour

    Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution

    Drug: bosutinib capsules low flavour

  • Experimental
    K - bosutinib capsules high flavour

    Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour

    Drug: bosutinib capsules high flavour

  • Experimental
    L - bosutinib capsules applesauce

    200 Mg of bosutinib (50 mg x 4 capsules) in applesauce

    Drug: bosutinib capsules in applesauce

  • Experimental
    M - bosutinib capsules full fat yougurt

    200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt

    Drug: Bosutinib capsules in yogurt

  • Experimental
    N - bosutinib capsules in water (retest)

    200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)

    Drug: bosutinib capsules in water

Interventions

  • Drug200 Mg capsules of bosutinib in Water solution

    200 mg (4X50) Capsules in water

  • Drugbosunitib sorbitol

    200 Mg of bosutinib sorbitol solution

  • DrugBosutinib Mannitol

    Bosutinib mannitol solution

  • Drugbosutinib in mannitol low sweet

    bosutinib in mannitol solution low sweet

  • Drugbosutinib in mannitol high sweet

    bosutinib in mannitol high sweet

  • Drugbosutinib taste low flavour

    bosutinib solution low flavour

  • Drugbosutinib high flavour

    bosutinib solution high flavour

  • Drugbosutinib capsules in applesauce

    Bosutinib capsules in applesauce

  • DrugBosutinib capsules in yogurt

    bosutinib capsules in yogurt

  • Drugbosutinib capsules in water

    sham comparator, bosutinb in water retest

  • DrugBosutinib capsules in low sweet

    bosutinib capsules in low sweet

  • Drugbosutinib capsules high sweet

    Bosutinib capsules high sweet

  • Drugbosutinib capsules low flavour

    Bosutinib capsules low flavour

  • Drugbosutinib capsules high flavour

    bosutinib capsules in high flavour

06

What researchers measure

Primary outcomes

  1. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib in Water)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  2. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib sorbitol)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  3. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib mannitol)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  4. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib mannitol low sweet)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  5. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use(Bosutinib mannitol high sweet)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  6. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib mannitol in low flavour strawberry)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  7. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib mannitol high flavour strawberry)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  8. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib 50 mg capsules X4) low sweet

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  9. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib 50 mg capsules X4) high sweet

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  10. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib 50 mg capsules X4) low flavour

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  11. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib 50 mg capsules X4) high flavour

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  12. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib 50 mg capsules X4) applesauce

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  13. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (bosutinib 4 capsules 50 mg bosutinib in yogurt

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

  14. Taste evaluation using Bosutinib Taste Assessment Questionnaire toward formulation for pediatric use (Bosutinib 50 mg capsules X4 in water retest)

    This study will enable the selection of the commercial formulation for pediatric use of bosutinib

    Time frame: baseline to one month

Secondary outcomes

  1. Number or treatment emergent treatment related adverse events following oral administration of bosutinib solution bosutinib 200 mg sorbitol

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: Baseline to one month

  2. Number or treatment emergent treatment related adverse events following oral administration of 200 mg bosutinib powder mannitol solution

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  3. Number of patients with treatment emergent treatment related adverse events bosutinib 50 mg x4 capsules in water

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  4. Number of patients with treatment emergent treatment related adverse events bosutinib 200 mg mannitol low sweet

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  5. number of patients with treatment emergent or treatment related adverse events bosutinib 200 mg mannitol high sweet

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  6. number of patients with treatment emergent treatment related adverse events bosutinib 200 mg mannitol high flavour (strawberry)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  7. Number or treatment emergent treatment related adverse events following oral administration of bosutinib 200 mg solution mannitol low flavour

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  8. Number or treatment emergent treatment related adverse events following oral administration of bosutinib solution 50 mg x 4 capsules high sweet

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  9. Number or treatment emergent treatment related adverse events following oral administration of bosutinib solution capsules 4 x 50mg low flavour

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  10. Number or treatment emergent treatment related adverse events following oral administration of bosutinib solution capsules 50 mg X4 high flavour

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  11. Number or treatment emergent treatment related adverse events following oral administration of bosutinib solution capsules 4 x 50 mg applesauce

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  12. Number or treatment emergent treatment related adverse events following oral administration of bosutinib solution capsules 50 mg x4 in yogurt

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  13. Number of treatment emergent treatment related adverse events following oral administration of 4 X50 mg capsules bosutinib low sweet solution

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

  14. Number of treatment emergent treatment related adverse events following oral administration of bosutinib 50 mg capsules x4 in water (retest)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Bosutinib was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: baseline to one month

07

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03747679
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Nov 22, 2018
Primary completion
Jan 14, 2019
Completion
Jan 14, 2019
Last update
Jul 10, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Pfizer

Start the discussion